Raia Drogasil (Raia Drogasil) Total Liabilities : $2,913 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Raia Drogasil Total Liabilities?

Raia Drogasil's Total Liabilities for the quarter that ended in Mar. 2024 was $2,913 Mil.

Raia Drogasil's quarterly Total Liabilities increased from Sep. 2023 ($2,752.05 Mil) to Dec. 2023 ($2,870.75 Mil) and increased from Dec. 2023 ($2,870.75 Mil) to Mar. 2024 ($2,913.11 Mil).

Raia Drogasil's annual Total Liabilities increased from Dec. 2021 ($1,778.41 Mil) to Dec. 2022 ($2,246.23 Mil) and increased from Dec. 2022 ($2,246.23 Mil) to Dec. 2023 ($2,870.75 Mil).

Raia Drogasil Total Liabilities Historical Data

The historical data trend for Raia Drogasil's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raia Drogasil Total Liabilities Chart

Raia Drogasil Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,990.95

1,827.60

1,778.41

2,246.23

2,870.75

Raia Drogasil Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2,443.20	2,501.95	2,752.05	2,870.75	2,913.11

Raia Drogasil Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Raia Drogasil's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1648.944	+	(1143.801	+	78.007
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,871

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4101.068	-	1230.316
	=	2,871

Raia Drogasil's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1684.081	+	(1155.487	+	73.541
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,913

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	4147.085	-	1233.976
	=	2,913

Raia Drogasil Total Liabilities Related Terms

Thank you for viewing the detailed overview of Raia Drogasil's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Raia Drogasil (Raia Drogasil) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (OTCPK:RADLY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RADL3:Brazil

Address

Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000

Website

https://ri.rd.com.br

Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.